Pahr Therapeutics has announced a $14 million seed financing round led by RA Capital Management, AN Venture Partners, and the University of Tokyo Edge Capital Partners (UTEC).
Founded in the Raven incubator of RA Capital Management and led by Neil Buckley, Pahr Therapeutics was co-founded by Drs. Yoshikazu Nakaoka, Makoto Okazawa, and Ryotaro Asano from the National Cerebral and Cardiovascular Center in Osaka, Japan. Dr. Nakaoka, an expert in PAH research, has significantly influenced the company’s therapeutic strategies.
Last year, he was a finalist at Science2Startup Japan, where his partnership with mentor Andrew Levin contributed to the establishment of Pahr Therapeutics.
How the funding will be used: The funding will advance the development of therapies for pulmonary arterial hypertension (PAH).
New board members: In conjunction with this financing, Andrew Levin, MD/PhD, Ken Horne, and Atsushi Usami, PhD, have been appointed to the board of directors.
KEY QUOTE:
“I am excited to work with RA Capital Management, AN Venture Partners, and UTEC to bring much needed new therapies to PAH patients. Having global investors support the company is inspiring for us, and we look forward to advancing into clinical studies early next year.”
Dr. Nakaoka
